Results 151 to 160 of about 25,852 (227)

Longitudinal assessment and predictors of subjective taste change after hematopoietic cell transplantation (HCT). [PDF]

Support Care Cancer
Hovan AJ, Brennan MT, Hasséus B, Raber-Durlacher JE, Huysmans MC, Laheij AMGA, van Leeuwen SJM, Legert KG, Isom S, Kline DM, Blijlevens NMA, Johansson JE, von Bültzingslöwen I.   +12 more
europepmc   +1 more source

Identification of immune reconstitution and hematopoiesis restoration by scRNA-seq in bone marrow of multiple myeloma patients treated with high-dose melphalan following auto-HSCT. [PDF]

Cancer Biol Med
Li Q, Wang Y, Yuan H, Cai Q, Zhao L, Lin L, Gao S, Chen L, Zhang Z, Ma J, Liu S, Cao Z, Zhao H, Wang Y, Li S, Lv P, Zhang H, Wang G, Yang G, Zhang X, Wang Y.   +20 more
europepmc   +1 more source

Autologous bone marrow transplantation in non-Hodgkin lymphoma patients following different conditioning regimens: an 11-year single-center quasi-experimental study. [PDF]

Blood Res
Tavakoli Shiraji S, Biglari M, Rad S, Barkhordar M, Foumani HK, Janbabaei G, Mousavi SA, Vaezi M, Mohammadi K, Ghavamzadeh A.   +9 more
europepmc   +1 more source

Flare of clonal hematopoiesis, TP53 expansion and prior melphalan drive post-CAR-T myeloid disorders in multiple myeloma. [PDF]

Leukemia
Waldschmidt J, Fandrei D, Hecker JS, Meggendorfer M, Truger M, Reinhard F, Shibru B, Högner M, Gebauer A, Köppel M, Müller H, Jung J, Teschner D, Topp MS, Purcarea A, Vučinić V, Haferlach T, Bassermann F, Platzbecker U, Einsele H, Haferlach C, Kortüm KM, Metzeler KH, Merz M, Götze KS, Rasche L.   +25 more
europepmc   +1 more source

Thalidomide as a rescue protocol for treatment of multiple myeloma in dogs: preliminary data from a multicentre retrospective study. [PDF]

Front Vet Sci
Ciccarelli S, Leo C, Perrone C, Franchini D, Bonazzi I, Finotello R.   +5 more
europepmc   +1 more source

Leveraging AI to Evaluate Minimal Residual Disease Endpoint Surrogacy in Multiple Myeloma. [PDF]

Cancer Res Commun
Ren Z, Zhao Z, Cowan AJ, Ma W, Xie E, Shi Q.   +5 more
europepmc   +1 more source

Durable Remission of Highly Refractory Multiple Myeloma and Therapy-Related MDS/AML After Allogeneic Hematopoietic Cell Transplantation: Reconsidering Its Role in the CAR-T Era. [PDF]

EJHaem
Kumamoto T, Yoshihara K, Samori M, Takahashi S, Yamagata F, Fujita Y, Utsunomiya N, Yoshihara S.   +7 more
europepmc   +1 more source

Oral chemotherapy agents in cats: clinical uses, administration and side effects. [PDF]

J Feline Med Surg
Lopes M, Morris J.
europepmc   +1 more source

Is Less "Sufficient" and "Safe" in the MRD Era - Outcomes of Autologous Stem-Cell Transplant as per Melphalan Dose in Patients with Multiple Myeloma. [PDF]

Blood Cancer J
Mirgh S, Goel A, Punatar S, Gokarn A, Jindal N, Chichra A, Nayak L, Bain G, Nashikkar C, Mahajan P, Deval K, Khan A, Tembhare P, Patkar N, Rajpal S, Chatterjee G, Kannan S, Mathew L, Subramanian P, Bagal B, Khattry N.   +20 more
europepmc   +1 more source

Netupitant/palonosetron is effective for preventing chemotherapy-induced nausea and vomiting in high-dose melphalan conditioning before autologous stem cell transplantation: A real-world analysis. [PDF]

Blood Sci
Cao LQ, Dai J, Wang T, Liu BN, Deng DX, Liu Y, Wang YY, Fan QL, Guo RY, Qu Y, Gao YQ, Qi XX, Liu MR, Qi XJ, Feng ZP, Mo XD.   +15 more
europepmc   +1 more source